Targeted radiation for advanced Hurthle cell thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new targeted radiation therapy (177Lu-DOTA-EB-TATE) for people with advanced Hurthle cell thyroid cancer that did not respond to radioactive iodine. The treatment aims to deliver radiation directly to cancer cells, potentially slowing tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be a rare type called Hurthle cell thyroid cancer that has spread to other parts of the body and did not respond to radioactive iodine treatment.
- Your tumors must have a high level of a specific receptor (SSTR2) as seen on a specialized PET scan.
- You cannot have serious kidney, liver, or bone marrow problems, or certain other unstable health conditions.
- You cannot be pregnant, breastfeeding, or have a history of severe allergic reactions to similar treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This study looks at people who have or may have thyroid nodules (lumps in the thyroid gland in your neck) or thyroid cancer, as well as family members who may have inherited a higher risk. It aims to better understand and diagnose these thyroid problems.
This trial tests a new type of PET scan (F-18 Tetrafluoroborate) to find thyroid cancer cells that don't show up on standard scans. It's for people who have had surgery and radioactive iodine therapy but still have signs of cancer in their blood tests.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.